Samsung Biologics, a leading contract development and manufacturing organization (CDMO), has introduced two proprietary development platforms—S-AfuCHOTM and S-OptiChargeTM—at BioProcess International 2024. These innovations are designed to enhance therapeutic efficacy and ensure high product quality in biopharmaceutical development.
S-AfuCHOTM is a cell line platform that generates afucosylated antibodies with increased antibody-dependent cellular cytotoxicity (ADCC) activity, improving therapeutic effects. The platform eliminates core fucose from Fc N-glycans, boosting ADCC while maintaining stability and product quality.
S-OptiChargeTM, an upstream process platform, modulates charge variant distribution to enhance product safety and efficacy. By optimizing critical parameters, it ensures tight control over charge variants, maximizing the desired molecular form in therapeutic products.
Samsung Biologics continues to expand its capabilities, including its Bio Campus II, to meet growing client demand for complex biopharmaceuticals. These new platforms demonstrate the company’s commitment to providing cutting-edge solutions for efficient and safe drug development.
